Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies
- PMID: 27522040
- DOI: 10.1016/j.bbmt.2016.08.003
Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies
Abstract
Most patients eligible for allogeneic hematopoietic stem cell transplantation will require identification of an alternate (unrelated or mismatched related) donor. We explored the transplantation outcomes for a sequential series of 54 patients undergoing haploidentical donor transplantation (HAPLO) compared to those from a control group of patients receiving cells from matched or mismatched unrelated donors (URD) selected by diagnosis and stem cell source. Patients undergoing HAPLO transplantations received graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (Cy). Day 15 neutrophil recovery was lower after HAPLO than in URD recipients (43% versus 77%, P < .001), as was day 30 platelet recovery (67% versus 84%, P = .043). HAPLO patients receiving bone marrow achieved neutrophil engraftment at a median of 17 days and platelet engraftment at a median of 29 days, compared with 16 days and 24 days, respectively, for recipients of peripheral blood stem cells. The incidence of graft failure was similar for both HAPLO and URD recipients (P = .42). HAPLO recipients were more likely to reach donor CD3 chimerism >95% by day 28 after transplantation (88% versus 62%, P = .003). The cumulative incidence of grades II to IV acute GVHD (aGVHD) at 6 months after transplantation did not differ for these 2 groups (63% for HAPLO and 53% for URD recipients; P = .269), nor did the cumulative incidence of severe grade III/IV aGVHD (13% for HAPLO and 8% for URD recipients; P = .44). The cumulative incidence of moderate or severe chronic GVHD at 2 years did not differ, with probabilities of 24% for HAPLO and 18% for URD recipients (P = .43). The cumulative incidence of cytomegalovirus reactivation by day 100 after transplantation did not differ (45% for HAPLO and 46% for URD recipients; P = .96). The HAPLO recipients experienced a lower incidence of Epstein-Barr virus reactivation by day 100 (6% versus 32%, P < .001) but a higher incidence of Human Herpesvirus-6 reactivation (35% versus 10%, P = .001). Relapse risk, regimen-related mortality, progression-free survival, and overall survival probabilities did not differ between these 2 groups. These data support the use of HAPLO transplantation with post-transplantation Cy as an alternate transplantation technique for patients lacking HLA-matched sibling donors. Transplantation of peripheral blood stem cells does not appear to enhance the speed of neutrophil recovery. The different patterns of viral reactivation require additional studies to explain.
Keywords: Haploidentical transplantation; Post-transplantation cyclophosphamide; Unrelated donor transplantation.
Copyright © 2016 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307. doi: 10.1016/j.bbmt.2015.03.003. Epub 2015 Mar 19. Biol Blood Marrow Transplant. 2015. PMID: 25797174 Clinical Trial.
-
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Cancer. 2016 Nov 15;122(21):3316-3326. doi: 10.1002/cncr.30180. Epub 2016 Jul 12. Cancer. 2016. PMID: 27404668 Free PMC article. Clinical Trial.
-
Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.Biol Blood Marrow Transplant. 2019 Dec;25(12):2422-2430. doi: 10.1016/j.bbmt.2019.07.028. Epub 2019 Aug 3. Biol Blood Marrow Transplant. 2019. PMID: 31386903
-
Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.Transplant Cell Ther. 2024 May;30(5):538.e1-538.e10. doi: 10.1016/j.jtct.2024.01.082. Epub 2024 Feb 6. Transplant Cell Ther. 2024. PMID: 38331195
-
Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.Crit Rev Oncol Hematol. 2019 Jan;133:120-128. doi: 10.1016/j.critrevonc.2018.05.017. Epub 2018 Jun 11. Crit Rev Oncol Hematol. 2019. PMID: 30661648
Cited by
-
Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation.Blood Sci. 2024 Jan 10;6(1):e00178. doi: 10.1097/BS9.0000000000000178. eCollection 2024 Jan. Blood Sci. 2024. PMID: 38213825 Free PMC article. Review.
-
Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.Blood Adv. 2017 Feb 14;1(6):401-406. doi: 10.1182/bloodadvances.2016002188. eCollection 2017 Feb 14. Blood Adv. 2017. PMID: 29296955 Free PMC article.
-
Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!Oncologist. 2017 Sep;22(9):1125-1134. doi: 10.1634/theoncologist.2017-0009. Epub 2017 May 25. Oncologist. 2017. PMID: 28546462 Free PMC article. Review.
-
Harnessing and honing mesenchymal stem/stromal cells for the amelioration of graft-versus-host disease.World J Stem Cells. 2023 Apr 26;15(4):221-234. doi: 10.4252/wjsc.v15.i4.221. World J Stem Cells. 2023. PMID: 37180998 Free PMC article. Review.
-
Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation.Cells. 2024 Jun 6;13(11):993. doi: 10.3390/cells13110993. Cells. 2024. PMID: 38891125 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials